Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | AGPAT2 | O15120 | 5/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18153298 | 0.84 | ABCG2 (0.54) | POLA1MAPTPOLBGAASMN1; SMN2 | |
| SCHEMBL7356335 | 0.82 | CYP1A2 (0.66) | MAPTABCG2ABCB1NPC1RAB9A | |
| SCHEMBL29609567 | 0.80 | POLA1 (0.67) | POLA1MAPTPOLBGAASMN1; SMN2 | |
| SCHEMBL3233125 | 0.80 | MAPT (0.70) | POLA1MAPTPOLBGAASMN1; SMN2 | |
| SCHEMBL28229117 | 0.80 | POLA1 (0.67) | POLA1MAPTPOLBGAASMN1; SMN2 | |
| SCHEMBL1320467 | 0.79 | KMT2A (0.66) | POLA1MAPTPOLBGAASMN1; SMN2 | |
| SCHEMBL4280314 | 0.79 | AGPAT2 (0.79) | ABCG2NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL4282006 | 0.78 | AGPAT2 (0.79) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1181905 | 0.77 | AGPAT2 (0.45) | POLA1MAPTPOLBGAASMN1; SMN2 | |
| SCHEMBL1182341 | 0.76 | ABCG2 (0.49) | ABCG2ABCB1NPC1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737153-B2 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-7737153-B2 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-7737153-B2 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-20060241127-A1 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER HEALTHCARE AG (DE) | 2006-10-26 | — | — | US | disclosed |
| EP-1562935-B1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2004039796-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241127-A1 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | ROCK1, ROCK2, RHOA | POLA1 2725/4885MAPT 2488/4885POLB 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.